Alfie, who Duchenne Muscular Dystrophy, wants to walk on the pitch at a Liverpool FC game and watch a football match abroad.

Wells Fargo on Thursday raised its price target on Sarepta Therapeutics, Inc. (SRPT) to $50 from $48 after the company’s ...

Detailed price information for Denali Therapeutics Inc (DNLI-Q) from The Globe and Mail including charting and trades.

Cancer vaccine experts are worried that if the Trump administration takes a hostile posture towards mRNA broadly, cancer ...

Edgewise Therapeutics Inc., (Nasdaq: EWTX), a Boulder-based muscle-disease biopharmaceutical company, maintained a strong cash balance in the second quarter as it proceeds with trials for treatment of ...

Sarepta did not hold an investor call for its second-quarter earnings report or provide an updated full-year revenue outlook.

Operator: Good afternoon, and welcome to the Cumberland Pharmaceuticals Second Quarter 2025 Financial Report and Company ...

Keros Therapeutics has shaken up its leadership structure as the bi | Keros has shaken up its leadership structure as the ...

Key Points Revenue grew 10% year-over-year to $10.8 million (GAAP) in Q2 2025, reflecting continued top-line gains, with GAAP net revenues of $10.8 million. Adjusted diluted earnings per share ...

After a second Elevidys patient death from acute liver failure, Sarepta in July launched a major restructuring that involves ...

Shares of Sarepta Therapeutics ( NASDAQ: SRPT) rose on Wednesday after the market as it reported second quarter revenue and ...

Sarepta Therapeutics hired a Trump-connected lobbying firm after the death of a teenage boy treated with its Duchenne ...